Gene therapy in tissue-engineered blood vessels.

Journal Article

Cardiovascular disease is the leading cause of morbidity and mortality in Western society. More than 1 million arterial bypass procedures are performed annually in the United States, where either autologous veins or synthetic grafts are used to replace arteries in the coronary or peripheral circulation. Tissue engineering of blood vessels from autologous cells has the potential to produce biological grafts for use in bypass surgery. Ex vivo development of vascular grafts also provides an ideal target of site-specific gene therapy to optimize the physiology of the developing conduit, and for the possible delivery of other therapeutic genes to a vascular bed of interest. In this article, we demonstrate that by using a novel retroviral gene delivery system, a target gene of interest can be specifically delivered to the endothelial cells of a developing engineered vessel. Further, we demonstrate that this technique results in stable incorporation of the delivered gene into the target endothelial cells for more than 30 days. These data demonstrate the utility of the retroviral gene delivery approach for optimizing the biologic phenotype of engineered vessels. This also provides the framework for testing an array of genes that may improve the function of engineered blood vessels after surgical implantation.

Full Text

Duke Authors

Cited Authors

  • Fields, RC; Solan, A; McDonagh, KT; Niklason, LE; Lawson, JH

Published Date

  • December 2003

Published In

Volume / Issue

  • 9 / 6

Start / End Page

  • 1281 - 1287

PubMed ID

  • 14670116

International Standard Serial Number (ISSN)

  • 1076-3279

Digital Object Identifier (DOI)

  • 10.1089/10763270360728198

Language

  • eng

Conference Location

  • United States